← Browse by Condition
Medical Condition

myeloid malignancy

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for myeloid malignancy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myeloid malignancy Clinical Trials

How many clinical trials are currently recruiting for myeloid malignancy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for myeloid malignancy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myeloid malignancy?
myeloid malignancy research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myeloid malignancy clinical trial?
Eligibility criteria for myeloid malignancy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
BeOne Medicines 1 trial
Hangzhou GluBio Pharmaceutical Co., Ltd. 1 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT07619287 Phase 1
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
Enrollment
118 pts
Location
Australia, China, Ne...
Sponsor
BeOne Medicines
View Trial →
NCT06378437 Phase 1
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
Enrollment
108 pts
Location
China
Sponsor
Hangzhou GluBio Pharmaceutical...
View Trial →
NCT07011186 Phase 1, Phase 2
Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
Enrollment
138 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic...
View Trial →

Related Conditions

polycythemia vera (1) essential thrombocythemia (1) myelofibrosis (1) myelodysplastic syndromes (1) acute myeloid leukemia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology